Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related genes in circulating CD34+ cells of MPNs. Regarding lab...
Saved in:
Main Authors: | Vladan P. Čokić, Olivera Mitrović-Ajtić, Bojana B. Beleslin-Čokić, Dragana Marković, Marijana Buač, Miloš Diklić, Nada Kraguljac-Kurtović, Svetozar Damjanović, Pavle Milenković, Mirjana Gotić, Puri K. Raj |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2015/453020 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Hematopoietic Niche in Myeloproliferative Neoplasms
by: Annette H. Schmitt-Graeff, et al.
Published: (2015-01-01) -
Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms
by: Raunak Rao, et al.
Published: (2020-01-01) -
Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
by: Patrycja Zielinska, et al.
Published: (2014-01-01) -
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
by: Sylvie Hermouet, et al.
Published: (2015-01-01) -
The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
by: Douglas Tremblay, et al.
Published: (2019-01-01)